Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, posaconazole (Noxafil®) cannot be endorsed for use within NHS Wales for the treatment of fungal infections in adults. |
||
|
||
Medicine details |
||
| Medicine name | posaconazole (Noxafil®) | |
| Formulation | 300 mg concentrate for solution for infusion | |
| Reference number | 2421 | |
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 10/03/2015 | |
| Date of issue | 11/03/2015 | |